Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates.

Area of Science:

• Neuroscience
• Biotechnology
• Pharmacology

Background:

• Alzheimer's disease (AD) is the most common dementia, currently incurable.
• Existing pharmacological strategies for AD have limitations.
• Developing effective treatments for AD remains a significant challenge.

Purpose of the Study:

• To develop targeted multimodal polypeptide-based nanoconjugates for potential Alzheimer's disease (AD) treatment.
• To evaluate the neuroprotective and neurotrophic potential of these nanoconjugates.
• To assess the efficacy of nanoconjugates in reducing amyloid aggregates and improving cognitive function in AD models.

Main Methods:

• Conjugation of propargylamine moieties, bisdemethoxycurcumin or genistein to polypeptide nanoconjugates.
• Addition of Angiopep-2 targeting moiety for enhanced blood-brain barrier (BBB) passage.
• In vitro studies using organotypic hippocampal culture to assess neuroprotection and neurotrophic effects.
• In vivo studies using APP/PS1 transgenic AD model mice to evaluate BBB penetration, brain distribution, amyloid reduction, and cognitive function.

Main Results:

• Polypeptide nanoconjugates demonstrated neuroprotection and neurotrophic effects, increasing dendritic density in hippocampal neurons.
• Angiopep-2 conjugation improved BBB passage and targeted nanoconjugate accumulation in neurogenic brain areas.
• Nanoconjugate treatment significantly reduced neurotoxic β-amyloid aggregate levels in AD model mice.
• Treatment rescued olfactory memory and object recognition impairments in APP/PS1 mice.

Conclusions:

• Targeted multimodal polypeptide-based nanoconjugates show promise as a novel therapeutic strategy for Alzheimer's disease.
• These nanoconjugates possess both neuroprotective and neurotrophic properties.
• The study highlights the potential of nanoconjugate-based drug delivery for CNS disorders like AD.